Abstract: An electronic shelf label positioning system, an electronic shelf label and a guide rail. The electronic shelf label positioning system includes the electronic shelf label, the guide rail, a PDA and a background server. The electronic shelf label includes a main control SoC, a card reader IC, a screen and a power supply device. The main control SoC is configured to control the screen display and to communicate with an AP. The power supply device is configured to supply power to the electronic shelf label. The guide rail includes a guide rail identification area and a label area. The label area is installed with a plurality of wireless labels each having a unique non-repeated ID number. The guide rail identification area is installed with an identity recognition device, which includes a guide rail ID consisting of the ID numbers of the wireless labels sequentially arranged and summarized.

Abstract: The present invention discloses a novel use of a pharmaceutical composition in the preparation of a medicament in the treatment of opioid-induced tolerance and addiction, in particular to the use of AC1 inhibitor NB001 and AC1&8 mixed inhibitors NB010 and NB011 in the preparation of a medicament in the treatment of opioid-induced tolerance and addiction.

Abstract: A device configured to be interposed between a lower layer and an upper layer of particles arranged inside a cylindrical shell, so as to limit or prevent the migration of particles between the layers.

Abstract: A device configured to be interposed between a lower layer and an upper layer of particles arranged inside a cylindrical shell, so as to limit or prevent the migration of particles between the layers.

Abstract: The present invention discloses a novel use of a pharmaceutical composition in the preparation of a medicament in the treatment of opioid-induced tolerance and addiction, in particular to the use of AC1 inhibitor NB001 and AC1&8 mixed inhibitors NB010 and NB011 in the preparation of a medicament in the treatment of opioid-induced tolerance and addiction.

Abstract: The present invention provides a new crystal form of 5-((2-(6-amino)-9H-purin-9-yl)ethyl)amino)pentan-1-ol, which has a relatively better effect in selectively inhibiting adenylate cyclase 1 and is capable of preparing a medicament for treating neuropathic pain and/or inflammatory pain.

Abstract: The present invention provides a new crystal form of 5-((2-(6-amino)-9H-purin-9-yl)ethyl)amino)pentan-1-ol, which has a relatively better effect in selectively inhibiting adenylate cyclase 1 and is capable of preparing a medicament for treating neuropathic pain and/or inflammatory pain.

Abstract: An electronic device includes a cover and a display module mounted on the cover, the cover includes a cover body and a seal gasket molded on the cover body, the seal gasket is molded from thermosetting rubber. The seal gasket is permanently clamped between the cover body and the display module.

Abstract: A screen installation device is used for assembling a screen plate to a frame, the screen installation device, and includes a positioning device and a plurality of connection devices. The positioning device is for locating the frame. The connection devices are detachably assembled to the positioning device and are arranged around the screen plate, and part of each connection device is located and retained between the screen plate and the frame to create a constant width gap between the screen plate and the frame.

Abstract: A cover includes a molded cover body and a light guide board molded so as to be integral with the cover body. The cover body defines a mounting hole for mounting a keypad or keyboard.

Abstract: An electronic device includes a cover and a display module mounted on the cover, the cover includes a cover body and a seal gasket molded on the cover body, the seal gasket is molded from thermosetting rubber. The seal gasket is permanently clamped between the cover body and the display module.

Abstract: A screen installation device is used for assembling a screen plate to a frame, the screen installation device, and includes a positioning device and a plurality of connection devices. The positioning device is for locating the frame. The connection devices are detachably assembled to the positioning device and are arranged around the screen plate, and part of each connection device is located and retained between the screen plate and the frame to create a constant width gap between the screen plate and the frame.

Abstract: A method for the combined treatment of neuronal and non-neuronal pain in mammals is provided comprising administration of adenylyl cyclase 1 inhibitors having the following general formula (1): (1) wherein: G, H, J and M are each N, or H and J are each C, and G and M are each N, S or O, or H, J and M are each C and G is N, S or O.

Abstract: A method of treating an undesirable AC8-related condition in a mammal is provided comprising the step of inhibiting AC8 in the mammal

Abstract: A method of treating chronic pain in a mammal is provided comprising the steps of inhibiting CaMKIV in the mammal and administering to the mammal a therapeutically effective amount of an opioid.

Abstract: A method for the combined treatment of neuronal and non-neuronal pain in mammals is provided comprising administration of adenylyl cyclase 1 inhibitors having the following general formula (1): (1) wherein: G, H, J and M are each N, or H and J are each C, and G and M are each N, S or O, or H, J and M are each C and G is N, S or O.

Abstract: A method of treating conditions associated with fear memory in a mammal is provided. The method comprises inhibiting NR2B receptors in the ACC of the animal.

Abstract: A method of treating conditions associated with fear memory in a mammal is provided which includes selective inhibition of a GluR6 receptor. Methods of screening for compounds useful to treat such conditions are also provided.

Abstract: Disclosed is method of down-regulating an activity associated with AC1, AC8 or both in a subject comprising administering to the subject an antagonist to AC1, AC8 or both in an amount sufficient to affect the antagonism.

Abstract: The present invention provides a method to determine the extent of neuronal degradation due to aging, a learning disability, or a neurological disorder, which includes: (a) stimulating a neuronal cell population under suitable conditions so as to induce a late-phase long term potentiation; (b) stimulating a normal neuronal cell population under suitable conditions so as to induce a late-phase long term potentiation; and (c) comparing the duration of the late-phase long term potentiation of the neuronal cell population in step (a) with that of the normal neuronal cell population of step (b) so as to determine the extent of neuronal degradation due to aging, the learning disability or the neurological disorder. The learning disability or neurological disorder may be Alzheimer's Disease, a degenerative disorder associated with learning, memory or cognitive dysfunction, cerebral senility, multi-infarct dementia and senile dementia, electric shock induced amnesia or amnesia.